This HTML5 document contains 149 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n8http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00544/identifier/wikipedia/
dctermshttp://purl.org/dc/terms/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00544/identifier/pharmgkb/
n10http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00544/identifier/kegg-compound/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00544/identifier/pdb/
n6http://linked.opendata.cz/resource/drugbank/dosage/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00544/identifier/pubchem-compound/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00544/identifier/pubchem-substance/
n12http://bio2rdf.org/drugbank:
n23http://linked.opendata.cz/resource/drugbank/drug/DB00544/identifier/kegg-drug/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00544/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n20http://linked.opendata.cz/resource/drugbank/drug/DB00544/identifier/national-drug-code-directory/
n13http://linked.opendata.cz/resource/drugbank/patent/
n14http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n15http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n27http://www.drugs.com/cdi/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00544/identifier/chemspider/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n25http://linked.opendata.cz/resource/drugbank/drug/DB00544/identifier/chebi/
n30http://linked.opendata.cz/resource/atc/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00544
rdf:type
n3:Drug
n3:description
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]
n3:dosage
n6:271B4379-363D-11E5-9242-09173F13E4C5 n6:271B437D-363D-11E5-9242-09173F13E4C5 n6:271B437E-363D-11E5-9242-09173F13E4C5 n6:271B437F-363D-11E5-9242-09173F13E4C5 n6:271B4380-363D-11E5-9242-09173F13E4C5 n6:271B4381-363D-11E5-9242-09173F13E4C5 n6:271B4382-363D-11E5-9242-09173F13E4C5 n6:271B437A-363D-11E5-9242-09173F13E4C5 n6:271B437B-363D-11E5-9242-09173F13E4C5 n6:271B437C-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Longley DB, Harkin DP, Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003 May;3(5):330-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12724731 # Petty RD, Cassidy J: Novel fluoropyrimidines: improving the efficacy and tolerability of cytotoxic therapy. Curr Cancer Drug Targets. 2004 Mar;4(2):191-204. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15032669
n3:group
approved
n3:halfLife
10-20 minutes
n3:indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
n3:manufacturer
n4:271B4361-363D-11E5-9242-09173F13E4C5 n4:271B435F-363D-11E5-9242-09173F13E4C5 n4:271B4360-363D-11E5-9242-09173F13E4C5 n4:271B435D-363D-11E5-9242-09173F13E4C5 n4:271B435E-363D-11E5-9242-09173F13E4C5 n4:271B4368-363D-11E5-9242-09173F13E4C5 n4:271B4366-363D-11E5-9242-09173F13E4C5 n4:271B4367-363D-11E5-9242-09173F13E4C5 n4:271B4364-363D-11E5-9242-09173F13E4C5 n4:271B4365-363D-11E5-9242-09173F13E4C5 n4:271B4362-363D-11E5-9242-09173F13E4C5 n4:271B4363-363D-11E5-9242-09173F13E4C5 n4:271B435B-363D-11E5-9242-09173F13E4C5 n4:271B435C-363D-11E5-9242-09173F13E4C5 n4:271B4359-363D-11E5-9242-09173F13E4C5 n4:271B435A-363D-11E5-9242-09173F13E4C5 n4:271B4358-363D-11E5-9242-09173F13E4C5 n4:271B4357-363D-11E5-9242-09173F13E4C5
owl:sameAs
n12:DB00544 n14:DB00544
dcterms:title
Fluorouracil
adms:identifier
n18:46508557 n19:3385 n20:0703-3015-13 n21:URF n22:C07649 n23:D00584 n24:DB00544 n25:46345 n26:3268 n28:Fluorouracil n29:PA128406956
n3:mechanismOfAction
The precise mechanism of action has not been fully determined, but the main mechanism of fluorouracil is thought to be the binding of the deoxyribonucleotide of the drug (FdUMP) and the folate cofactor, N5–10-methylenetetrahydrofolate, to thymidylate synthase (TS) to form a covalently bound ternary complex. This results in the inhibition of the formation of thymidylate from uracil, which leads to the inhibition of DNA and RNA synthesis and cell death. Fluorouracil can also be incorporated into RNA in place of uridine triphosphate (UTP), producing a fraudulent RNA and interfering with RNA processing and protein synthesis.
n3:packager
n4:271B433F-363D-11E5-9242-09173F13E4C5 n4:271B4340-363D-11E5-9242-09173F13E4C5 n4:271B433E-363D-11E5-9242-09173F13E4C5 n4:271B4343-363D-11E5-9242-09173F13E4C5 n4:271B4344-363D-11E5-9242-09173F13E4C5 n4:271B4341-363D-11E5-9242-09173F13E4C5 n4:271B4342-363D-11E5-9242-09173F13E4C5 n4:271B4347-363D-11E5-9242-09173F13E4C5 n4:271B4348-363D-11E5-9242-09173F13E4C5 n4:271B4345-363D-11E5-9242-09173F13E4C5 n4:271B4346-363D-11E5-9242-09173F13E4C5 n4:271B434B-363D-11E5-9242-09173F13E4C5 n4:271B4349-363D-11E5-9242-09173F13E4C5 n4:271B434A-363D-11E5-9242-09173F13E4C5 n4:271B433D-363D-11E5-9242-09173F13E4C5 n4:271B434C-363D-11E5-9242-09173F13E4C5 n4:271B433C-363D-11E5-9242-09173F13E4C5 n4:271B434F-363D-11E5-9242-09173F13E4C5 n4:271B4350-363D-11E5-9242-09173F13E4C5 n4:271B434D-363D-11E5-9242-09173F13E4C5 n4:271B434E-363D-11E5-9242-09173F13E4C5 n4:271B4353-363D-11E5-9242-09173F13E4C5 n4:271B4354-363D-11E5-9242-09173F13E4C5 n4:271B4351-363D-11E5-9242-09173F13E4C5 n4:271B4352-363D-11E5-9242-09173F13E4C5 n4:271B4355-363D-11E5-9242-09173F13E4C5 n4:271B4356-363D-11E5-9242-09173F13E4C5
n3:patent
n13:6670335
n3:routeOfElimination
Seven percent to 20% of the parent drug is excreted unchanged in the urine in 6 hours; of this over 90% is excreted in the first hour. The remaining percentage of the administered dose is metabolized, primarily in the liver.
n3:synonym
5-Fluorouracil FU Fluouracil 5-Fluracil 5-Fluoropyrimidine-2,4-dione Fluorouracilo Fluoro Uracil Fluorouracil 5-FU Fluorouracilum 5-Fluoracil
n3:toxicity
LD<sub>50</sub>=230mg/kg (orally in mice)
n9:hasAHFSCode
n10:84-92-00 n10:10-00-00
n3:foodInteraction
Vitamin B1 needs increased with long term use.
n3:proteinBinding
8-12%
n3:synthesisReference
Leroy B. Townsend, Robert A. Earl, Steven J. Manning, "Method of synthesizing 1-(tetrahydro-2-furanyl)-5-fluorouracil." U.S. Patent US3960864, issued October, 1969.
foaf:page
n8:carac.htm n27:fluorouracil.html
n3:IUPAC-Name
n5:271B4387-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B438D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B438C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B4389-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B438A-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B438B-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B439D-363D-11E5-9242-09173F13E4C5 n5:271B4385-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B439F-363D-11E5-9242-09173F13E4C5 n5:271B4383-363D-11E5-9242-09173F13E4C5 n5:271B4386-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B43A0-363D-11E5-9242-09173F13E4C5 n5:271B4384-363D-11E5-9242-09173F13E4C5
n3:pKa
n5:271B43A1-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n30:L01BC02
n3:H-Bond-Acceptor-Count
n5:271B4393-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B4394-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B438E-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B438F-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B4391-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B4390-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B4392-363D-11E5-9242-09173F13E4C5
n3:absorption
28-100%
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
51-21-8
n3:category
n3:containedIn
n15:271B4378-363D-11E5-9242-09173F13E4C5 n15:271B436E-363D-11E5-9242-09173F13E4C5 n15:271B436F-363D-11E5-9242-09173F13E4C5 n15:271B436A-363D-11E5-9242-09173F13E4C5 n15:271B436B-363D-11E5-9242-09173F13E4C5 n15:271B4369-363D-11E5-9242-09173F13E4C5 n15:271B4370-363D-11E5-9242-09173F13E4C5 n15:271B4371-363D-11E5-9242-09173F13E4C5 n15:271B436C-363D-11E5-9242-09173F13E4C5 n15:271B436D-363D-11E5-9242-09173F13E4C5 n15:271B4374-363D-11E5-9242-09173F13E4C5 n15:271B4375-363D-11E5-9242-09173F13E4C5 n15:271B4372-363D-11E5-9242-09173F13E4C5 n15:271B4373-363D-11E5-9242-09173F13E4C5 n15:271B4376-363D-11E5-9242-09173F13E4C5 n15:271B4377-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B4399-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B439B-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B439C-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B439E-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B4398-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B4397-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B439A-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B4388-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B4395-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B4396-363D-11E5-9242-09173F13E4C5